Other options include the use of brentuximab vedotin, bendamustine, rituximab, mTOR inhibitors (e.g., everolimus), immunomodulators (e.g., lenalidomide), histone deacetylase inhibitors, adoptive immunotherapy, local regional irradiation, or allogeneic SCT.17–26 In addition, the anti PD-1 antibody nivolumab has shown quite impressive responses in patients with HL who relapsed after prior autologous SCT.27 Allogeneic SCT is usually offered to patients with HL as a salvage therapy following relapse or progression after autologous SCT. Here, MTOR is linked to Hodgkins lymphoma.